Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY）
This is a phaseⅠb/Ⅱ, open-label, two-arm parallel study evaluating the efficacy and safety of different targeted antibody-drug conjugates for HER2 ultra-low or no expression advanced breast cancer
Breast Cancer
DRUG: SHR-A1811|DRUG: TROP2 ADC
Occurrence of adverse events (AEs)- Phase 1, Occurrence of AEs in Phase 1 graded according to CTCAE v5.0, Up to follow-up period, approximately 24 months|Objective Response Rate (ORR)- Phase 2, The proportion of patients who have a CR or PR, as determined by the Investigator at local site per RECIST 1.1., Until progression, assessed up to approximately 24 months
Progression Free Survival (PFS, Time to progression as assessed by the Investigator at local site per RECIST 1.1, or death due to any cause., Until progression, assessed up to approximately 24 months|Overall Survival (OS), time to death due to any cause, Until death, assessed up to approximately 24 months|Duration of Response (DoR), Time from the date of first documented response until the date of documented progression or death in the absence of disease progression., Until progression, assessed up to approximately 24 months|Disease Control Rate (DCR), The proportion of patients who have a CR or PR or SD, as determined by the Investigator at local site per RECIST 1.1., Baseline through end of study, assessed up to 24 months|Clinical Benefit Rate (CBR), The percentage of subjects with CR, PR and SD≥24 weeks，as determined by the Investigator at local site per RECIST 1.1., Until progression or death, assessed up to approximately 24 months|Exploratory analyses, HER2-PET was done at baseline to further explore the clinical utility of HER2-PET for HER2 detection, Baseline until disease progression or loss of clinical benefit, assessed up to 24 months|Safety, Occurrence of Adverse Events(AEs) graded according to CTCAE v5.0, Up to follow-up period, approximately 24 months
This is a phaseⅠb/Ⅱ, open-label, two-arm parallel study evaluating the efficacy and safety of different targeted antibody-drug conjugates for HER2 ultra-low or no expression advanced breast cancer